echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > PI3K dual inhibitor!

    PI3K dual inhibitor!

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    On April 19, CSPC announced that its subsidiary CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.
    , Ltd.
    's Duensibu Capsules (trade name: Kebituo) has been approved by the China National Medical Products Administration ( NMPA) accepted and received conditional approval for listing and priority review qualifications.

    According to the announcement, Duensibu Capsules are declared in accordance with category 5.
    1 of chemical drugs for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) who have undergone at least two lines of treatment in the past.
    The U.
    S.
    FDA approved the product for marketing in September 2018 and is the first approved dual inhibitor of PI3K-δ and PI3K-γ.
    CSPC holds the exclusive license for the development and commercialization of this product in China (including Hong Kong, Macau and Taiwan).

    According to public information, it is speculated that the new drug is Copiktra (duvelisib) introduced by CSPC from Verastem Oncology in September 2018.
    It can simultaneously inhibit the activities of PI3K-δ and PI3K-γ.
    These two protein kinases help support the survival and growth of cancerous B cells.

    Duvelisib's approval in the United States for the treatment of FL is mainly based on a single-arm, multi-center phase 2 clinical trial.
    83 FL patients who developed resistance to rituximab and chemotherapy or radiotherapy were treated with duvelisib.
    The results showed that the ORR reached 42%, of which 41% of patients had partial remission and 1 patient had complete remission.
    Among the patients who achieved remission, 43% had remission for more than 6 months, and 17% had remission for more than 12 months.

    Follicular lymphoma is a common type of lymphoma and the most common type of indolent lymphoma.
    The incidence of non-Hodgkin’s lymphoma is second only to diffuse large B-cell lymphoma, and it is easy to transform into diffuse large B-cell lymphoma.
    , The feature of extremely high recurrence rate after remission.
    In recent years, immunochemotherapy has gradually replaced chemotherapy and radiotherapy, and has shown good clinical treatment effects for different types of lymphomas.
    However, its safety, persistence of drug effects and selection of tumor indications are still facing bottlenecks, and clinical innovations are still needed.
    To meet demand.

    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
    If you need guidance on treatment plans, please go to a regular hospital for treatment.

    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
    If you need guidance on treatment plans, please go to a regular hospital for treatment.

    Reference materials:

    Reference materials:

    [1]Voluntary Announcement-The National Medical Products Administration accepts the listing application of "Duensibu Capsules".
    Retrieved Apr 19 2021, from 1209730780&orgId=gshk0001093&announcementTime=2021-04-19

    [1]Voluntary Announcement-The National Medical Products Administration accepts the listing application of "Duensibu Capsules".
    Retrieved Apr 19 2021, from 1209730780&orgId=gshk0001093&announcementTime=2021-04-19

    attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.